Prognosis at 6 Months for Coronary and Cerebrovascular Patients: Impact of Antiplatelet Agents and Statins: Results from the Prevenir III Study

Author： Ferrières Jean   Cambou Jean-Pierre   Cantet Christelle   Guize Louis  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.20, Iss.1, 2006-02, pp. : 55-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Variability in the Diagnosis and Management of Patients with Alzheimer's Disease and Cerebrovascular Disease: Results from the GALATEA Multicentre, Observational Study

By Gil Pedro  

Clinical Drug Investigation, Vol. 28, Iss. 7, 2008-01 ,pp. : 429-437

Adis International

Access to resources Recommend Favorite

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

By Satoh Taroh  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1511-1518

Springer Publishing Company

Access to resources Recommend Favorite

Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention: How Many and How Much?

By Duffy Brendan   Bhatt Deepak L.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 5, 2005-01 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite

The Antiplatelet and Antithrombotic Actions of Statins

By  

Current Pharmaceutical Design, Vol. 16, Iss. 34, 2010-11 ,pp. : 3808-3814

Bentham Science Publishers

Access to resources Recommend Favorite

Antiplatelet Agents and Anticoagulants: From Pharmacology to Clinical Practice

By  

Current Pharmaceutical Design, Vol. 23, Iss. 9, 2017-04 ,pp. : 1279-1293

Bentham Science Publishers

Access to resources Recommend Favorite